Inherited platelet disorders (IPD) are a heterogeneous group of rare disorders that affect platelet number and function and often predispose to other significant medical complications. In spite of the identification of over 50 IPD disease-associated genes, a molecular diagnosis is only identified in a minority (10%) of affected patients without a clinically suspected etiology. We studied a cohort of 21 pediatric patients with suspected IPDs by exome sequencing (ES) to: (1) examine the performance of the exome test for IPD genes, (2) determine if this exome-wide diagnostic test provided a higher diagnostic yield than has been previously reported, (3) to evaluate the frequency of variants of uncertain significance identified, and (4) to identify candidate variants for functional evaluation in patients with an uncertain or negative diagnosis. We established a high priority gene list of 53 genes, evaluated exome capture kit performance, and determined the coverage for these genes and disease-related variants. We identified likely disease causing variants in 5 of the 21 probands (23.8%) and variants of uncertain significance in 52% of patients studied. In conclusion, ES has the potential to molecularly diagnose causes of IPD, and to identify candidate genes for functional evaluation. Robust exome sequencing also requires that coverage of genes known to be associated with clinical findings of interest need to be carefully examined and supplemented if necessary. Clinicians who undertake ES should understand the limitations of the test and the full significance of results that may be returned.
| I N TR ODU C TI ON
Inherited platelet disorders (IPDs), are complex, genetically heterogeneous, and may have a mild clinical presentation making diagnosis challenging. 1, 2 Hematological and biochemical diagnostic assays are essential for clinical diagnostics, and genomic evaluation and identification of a molecular etiology can be critical to guide optimal treatment and follow up, as well as family counseling. As part of the Clinical Sequencing Exploratory Research (CSER) consortium 3 whose goals include the integration of genomic sequencing into clinical care via multidisciplinary approaches across a spectrum of symptomatic and healthy children and adults, 3 the Children's Hospital of Philadelphia (CHOP) Pediatric Sequencing (PediSeq) project focuses on determining best practices for genomic sequencing of pediatric patients with genetically heterogeneous conditions, including IPDs, risk for sudden cardiac arrest, 4 hearing loss, intellectual disability/developmental delay, and mitochondrial disorders.
Some IPDs, although rare, are clinically severe making diagnosis straightforward; however other disorders, such as some inherited thrombocytopenias may never present with a clinically significant bleeding event and are only identified incidentally by routine blood tests. In the latter cases, differentiation of an IPD from a secondary form of low platelet count such as immune thrombocytopenia is important for clinical management. Other patients with mild bleeding phenotypes can be diagnosed at a late age and represent a spectrum of disorders that are likely to be multifactorial and more common than previously thought. 5 Overall, these issues make connecting genetic variation to an underlying IPD very challenging and an unmet medical need. 6 Guidelines have been proposed for the evaluation of patients with suspected inherited platelet function disorders, 7 however, the recommended functional tests are not available in all centers and cannot be easily performed on shipped specimens. Molecular evaluation via sequencing is late in the algorithmic process, due to similar lack of availability and difficulty in classifying rare novel variants as pathogenic (as opposed to benign polymorphisms) which results in identification of many "variants of uncertain significance" (VUS), which are frustrating for patients and physicians alike. 8 One major challenge in predicting the clinical significance of novel missense variants is the frequent lack of functional evidence. 9 Recently, research and diagnostic laboratories have begun the process of including Next Generation Sequencing (NGS) panel-based assays within their workflows for the molecular diagnosis of IPD. 10, 11 Additionally, ES provides an effective method for diagnosis in both established IPD genes and discovery of new IPD disease genes. 12 Our overall goal was to determine the utility and limitations of ES for analysis and molecular diagnosis of a heterogeneous IPD cohort at a large urban academic pediatric hospital with the following objectives:
(1) examine the performance of the exome test for IPD genes, (2) determine if this exome-wide diagnostic test provided a higher diagnostic yield than has been previously reported, (3) evaluate the frequency of variants of uncertain significance identified, and (4) identify candidate variants for further functional evaluation in patients with an uncertain or negative diagnosis.
| M E TH ODS

| Overview of the study population
Patients were eligible for enrollment if they had a suspected inherited thrombocytopenia or platelet function disorder. All of the patients were followed at the Children's Hospital of Philadelphia (CHOP) Hemo- Table S1 ). Clinical diagnoses for the individuals included two (9.6%) with severe, congenital thrombocytopenia, two (9.6%) with dense granule deficiency, eight (38.1%) with macrothrombocytopenia, one (4.8%) with mild macrothromobocytopenia and platelet dysfunction, five (23.8%) with primarily platelet dysfunction, one (4.8%) with significant bleeding diathesis due to platelet dysfunction that has not been able to be better characterized, and two (9.6%) patients with thrombocytopenia with normal size platelets.
Eleven patients were male (52.4%) and ten were female (47.6%). The average age was 11.5 years. Seventeen individuals were White/Caucasian (81.0%), three were Black/African-American (14.3%) and one was more than one race. In terms of ethnicity, all individuals identified as non-Hispanic. There was a positive family history in nine individuals (42.9%). Eleven individuals had some type of previous genetic testing (52.4%).
| DNA isolation and exome sequencing
DNA isolation and exome sequencing was conducted as previously described. 4 Briefly, peripheral blood was collected from patients and stored at 48 C until genomic DNA was extracted using the Gentra 
| Creation of the pediatric IPD gene list
Genes associated with platelet disorders were manually curated based on review of the literature. Genes were included that were definitively associated with platelet disease as well as those with some evidence suggesting a possible role in platelet disorder etiology, taking into consideration the quality of evidence based on case reports, animal models, and in vitro cellular experimental models. Where available, evidence on mechanism(s) of pathogenicity, inheritance pattern, age of onset, prevalence and genotype-phenotype relationships were determined for accurate and robust interpretation of sequence variants (see "Variant interpretation workflow" section for additional details). 
| Variant interpretation workflow
| IPD candidate variant analysis
For the 16 patients in our cohort for whom a positive molecular diagnosis was not achieved by ES using our IPD gene list, an unbiased analysis of rare heterozygous, homozygous, and potential compound heterozygous variants was performed without using a gene list assessing the zygosity, predicted exonic effect, and incidence of mutations within shared genes among patients based on their IPD phenotype (TCP, MTCP, and PFD). In patients with more than one phenotype (i.e.,: Table S2 ).
These 53 genes included 873 exons with a range of one to 55 exons per gene.
| Performance of exome sequencing for diseaseassociated variant identification
We analyzed the performance of the Agilent SureSelect v4 capture kit with respect to these exons and 808 of 873 exons (92.6%) were targeted as defined in the Methods section (Supporting Information   Table S3 ). At least one exon was targeted for all of the 53 IPD genes and 28 genes (52.8%) had all known exons targeted. We analyzed the depth of coverage and found 76.7% of the 873 exons were completely covered with 100% of bases sequenced at 20X depth or greater on average across 265 identically-processed samples in our entire PediSeq cohort sequenced at an overall 100X depth of coverage ( Figure 1A and Supporting Information Table S4 ). Of the 808 targeted exons, 77.6%
were completely covered, and 66.0% of the 65 nontargeted exons were completely covered.
In order to determine if previously reported disease causing variants in these genes would have been detected, we searched the Human Genome Mutation Database (HGMD) for variants in the 53
IPD genes and identified 2 835 total variants that were classified by HGMD as potentially disease-associated ( Figure 1B ). Two hundred fifty six (9.0%) of these variants were excluded from analysis as they were not expected to be identified by exome sequencing, including large (>20 bp) deletions, insertions, duplications, indels and complex rearrangements. Therefore, 2 579 variants were further analyzed. These Table S5 ).
We also evaluated the depth of coverage across the IPD exons in order to determine the likelihood of detecting these variants in our pipeline. We randomly selected 95 IPD disease-associated variants (with a maximum of two variants per gene to minimize bias against genes with considerably more disease associated variants than others) and evaluated depth of coverage in a cohort of 265 individuals sequenced as part of our PediSeq study for various clinical indications.
We found that 88 of 95 (92.6%) variants had adequate sequencing read depth of 20X or greater on average across the 265 exomes (Supporting Information Table S6 ). For the remaining seven variants, four Figure S4 ), and was confirmed by Sanger sequencing using primers specific to the functional gene and not the pseudogene. 24 We achieved an overall positive molecular diagnostic yield of Table 2 . In an attempt to improve diagnostic yield, a modified ExomeDepth workflow for CNV detection was used to detect potential CNVs in the IPD gene list (manuscript in preparation). We found only one CNV of uncertain significance involving an IPD gene, a 188 kb duplication on chromosome 10 including ABI1, ANKRD26, LINC00202-1 in a patient with a molecular diagnosis (187).
To examine whether diagnostic rates differed based on clinical diagnosis, we categorized patients into four groups including thrombocytopenia (TCP, 4 patients), macrothrombocytopenia (MTCP, 8 patients), platelet function disorder (PFD, 7 patients), and platelet function disorder with thrombocytopenia/macrothrombocytopenia (PFD and TCP, 2 patients) (Supporting Information Figure S3 ). The TCP group had the highest positive diagnostic rate (50%, or 2 out of 4 patients), followed by the MTCP group with 25% (2 out of 8 patients), PFD with 14.2% (1 out of 7 patients), and PFD and TCP with no positive diagnoses. The remaining 75% (6 out of 8 patients) in the MTCP group had an uncertain diagnosis. In addition to a low positive diagnostic rate, the PFD group also had the largest negative diagnostic rate (57.1%, or 4 out of 7 patients).
We also examined whether there was an association between a reported family history and molecular diagnosis. There was a positive family history reported in nine patients (42.9%) in our cohort, with the TCP group having the highest reported family history (75%, or 3 out of 4 patients) (Supporting Information Figure S5A ). Overall, across all groups, 33.3% (4 out of 12 patients) with a negative family history received a positive molecular diagnosis, while only 11.1% (1 out of 9 patients) with a positive family history received a positive molecular diagnosis, however this difference was not statistically significant (twotailed P 5 .338, Fisher's exact test) (Supporting Information Figure S5B ).
For the self-identified non-White/Caucasian patients, one patient who was more than one race (patient 142) received an uncertain diagnosis, and three Black/African-American patients (patients 175, 184, 187)
received an uncertain, negative, and positive diagnosis, respectively.
For the 16 patients in our cohort for whom a positive molecular diagnosis was not achieved by ES using our IPD gene list, an unbiased analysis of rare heterozygous, homozygous, and potential compound heterozygous variants was performed without using a gene list assessing the zygosity, predicted exonic effect, and incidence of mutations within shared genes among patients based on their IPD phenotype (TCP, MTCP, and PFD) (Supporting Information Figure S1 ). In terms of zygosity, 2207 (95.8%) of the variants remaining after filtering were heterozygous, nine (0.4%) were homozygous, 16 (0.7%) were X-linked, and 72 (3.1%) were potentially biallelic (Supporting Information Table   S7 ). In terms of functional protein impact of the variants, 90.6% were an analysis examining high quality exome data in nontarget regions. 26 Although the primary goal of this study was not to maximize diagnostic yield, we achieved a positive molecular diagnosis in 23.8% of our cohort (5 of 21 unrelated patients). This molecular diagnostic rate is within the range of previously reported exome and gene panel positive diagnostic rates for platelet disorders (10.5% to 45.9%), 10, 12 for ES applied broadly in individuals with various phenotypes (20-36%), [27] [28] [29] [30] [31] [32] [33] and for pediatric patients with risk for sudden cardiac arrest in the PediSeq cohort (17%). 4 Approximately 250 gene-disease and 9200 variant-disease associations are reported annually, and this information prompts re-analysis of ES data as an attractive way improve diagnostic yield. 34 Wenger et al.found a molecular diagnosis in 10% of negative exome cases (with an average lag time of 20 months before re-analysis) due to new supporting literature where the evidence to associate the causative variant had previously been weak or nonexistent. This highlights the significant possibility that the causative disease variants in negative cases do not necessarily fall outside of the exome data already generated. One advantage of our ES IPD gene list approach is that newly-associated disease genes that were initially targeted but ignored for analysis can be easily included into the gene list filter for analysis without additional capture and sequencing, provided they had sufficient capture and were identified in this region in our cohort. However, these findings highlight the need to be aware of molecular mechanisms of pathogenicity when designing panels using ES workflows, 50 in addition to limitations of the tests selected.
We acknowledge the possibility of large structural variation or copy number variation (CNVs) to have an etiological role in our patients lacking a positive molecular diagnosis. While the current gold-standard method for performing CNV analysis is copy-number microarray, there are currently over 15 publically-available algorithms available that detect copy number variation based on ES sequencing read depth (reviewed by Kadalayil et al. 51 ). While this method did not improve our molecular diagnostic rate, it will be interesting to see how future pipelines that incorporate these increasingly sensitive and powerful techniques increase ES diagnostic yield and utility, and current studies in the laboratory are ongoing to evaluate their utility.
In the process of variant classification, we interpreted a total of 49 variants after filtering and retaining only rare nonsynonymous variants ( VWF has the largest number of disease-associated variants in HGMD out of all genes tested, and the largest number that were predicted to be missed due to reduced capture and coverage. Accurately identifying variants in regions homologous with pseudogenes is a significant problem with NGS, and longer read length technologies and protocol modifications will hopefully ameliorate some of these issues. 54 We identified six VWF variants in six patients by ES, one of which was in the partially processed pseudogene region (exon 30). Validation by Sanger sequencing using primers specific for the real gene 24 showed concordance with the ES results, however this region had reduced capture and coverage. Pseudogenes for ANKRD26, CYCS, and TUBB1 also exist, however, these were of less diagnostic significance in our study as no rare variants were identified by ES within ANKRD26 or CYCS, and only two likely benign variants were identified within TUBB1. These results demonstrate a common theme that although overall coverage may be high, clinicians should be aware that clinical utility will vary considerably across genes and a highly suspected gene of interest with no pathogenic variants may require further inspection by orthogonal methods.
| C ONC LUSI ON S
We evaluated ES-based molecular diagnostics in a cohort of 21 pediatric patients with IPDs and found it performed at or above the expected diagnostic rate. This is the first report of an exclusively pediatric plate- 
